by Portfolio Grader | February 13, 2013 3:00 pm
This week, five Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Dyax (NASDAQ:DYAX) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Dyax is engaged in the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. In Portfolio Grader’s specific subcategory of Sales Growth, DYAX also gets an A. For more information, get Portfolio Grader’s complete analysis of DYAX stock.
Nanosphere Inc. (NASDAQ:NSPH) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform. For more information, get Portfolio Grader’s complete analysis of NSPH stock.
Medivation’s (NASDAQ:MDVN) ratings are looking better this week, moving up to an A from last week’s B. Medivation acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. For more information, get Portfolio Grader’s complete analysis of MDVN stock.
Gilead Sciences (NASDAQ:GILD) improves from a B to an A rating this week. Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of GILD stock.
This week, Array BioPharma’s (NASDAQ:ARRY) ratings are up from a C last week to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/02/5-biotechnology-stocks-to-buy-now-dyax-nsph-mdvn/
Short URL: http://invstplc.com/1fsWQfC
Copyright ©2016 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.